StockNews.AI
HCM
StockNews.AI
2 hrs

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

1. HUTCHMED to host R&D update on October 31, 2025. 2. Dr. Shi will present insights on R&D strategy and candidate HMPL-A251. 3. The event emphasizes late-stage pipeline development for targeted therapies. 4. Webcasts available for broader audience engagement, enhancing investor interest. 5. Company positioned for growth in cancer and immunological disease treatments.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming R&D update may excite investors, as positive developments could enhance market position. Historical examples show that positive drug trial news often boosts stock prices significantly.

How important is it?

The focus on pipeline updates and strategic direction is critical for HCM's valuation. Stakeholder engagement during the R&D event can drive demand and improve share price.

Why Short Term?

Immediate investor interest expected from the R&D update event. Similar past events have led to short-term price movements influenced by public announcements.

Related Companies

NVSBMYAMGN
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — September 11, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025. During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will share insights into the Company’s R&D strategy and vision. This will include an overview of the Company’s Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development. The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and conducted in Chinese (Putonghua). A live webcast will be available concurrently. Attendance at the in-person event is by invitation only. A webcast in English will be held from 8:00 p.m. HKT / 8:00 a.m. EDT / 12:00 noon GMT on Friday, October 31, for approximately one hour. Both webcasts will be available live via the company website at www.hutch-med.com/event/. A replay will also be available on the website shortly after the event. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. CONTACTS Investor Enquiries+852 2121 8200 / ir@hutch-med.com  Media Enquiries FTI Consulting –+44 20 3727 1030 / HUTCHMED@fticonsulting.comBen Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000  

Related News